APA (7th ed.) Citation

M, H. S., J, C., B, W., A, W., S, S., L, S., . . . N, B. (2025). Matrix-directed therapy losartan to identify the effect on the bone resorption marker carboxy-terminal crosslink of type I collagen telopeptide (CTX) in older adolescents and adults with osteogenesis imperfecta recruited from secondary care sites: The 'MOI-A' study; a randomised, phase 2/pilot, dose-escalating trial. BMJ open, 15(12), e107243. https://doi.org/10.1136/bmjopen-2025-107243

Chicago Style (17th ed.) Citation

M, Haji Sadeghi, et al. "Matrix-directed Therapy Losartan to Identify the Effect on the Bone Resorption Marker Carboxy-terminal Crosslink of Type I Collagen Telopeptide (CTX) in Older Adolescents and Adults with Osteogenesis Imperfecta Recruited from Secondary Care Sites: The 'MOI-A' Study; a Randomised, Phase 2/pilot, Dose-escalating Trial." BMJ Open 15, no. 12 (2025): e107243. https://doi.org/10.1136/bmjopen-2025-107243.

MLA (9th ed.) Citation

M, Haji Sadeghi, et al. "Matrix-directed Therapy Losartan to Identify the Effect on the Bone Resorption Marker Carboxy-terminal Crosslink of Type I Collagen Telopeptide (CTX) in Older Adolescents and Adults with Osteogenesis Imperfecta Recruited from Secondary Care Sites: The 'MOI-A' Study; a Randomised, Phase 2/pilot, Dose-escalating Trial." BMJ Open, vol. 15, no. 12, 2025, p. e107243, https://doi.org/10.1136/bmjopen-2025-107243.